lacks 65 N-terminal amino acids. 2 SLC4A1 gene mutations have been reported to cause either RBC or renal abnormalities. In RBC membrane, band 3, which represents about 30% of the total amount of proteins, is part of a protein complex that plays an important role in the stability of RBC structure. 3, 4 SLC4A1 mutations affecting RBCs provoke abnormalities such as ovalocytosis or spherocytosis. 5 In the kidney, the main role of kAE1 is to extrude HCO 3 at the basolateral membrane of a-ICs, which is a critical step for renal acidification. When impaired, intracellular HCO 3 accumulates and blocks intracellular generation of protons and HCO 3 from CO 2 , and this ultimately inhibits apical proton secretion by the v-H þ -ATPase. 6 Accordingly, SLC4A1 mutations affecting kAE1 lead to type 1 distal renal tubular acidosis (dRTA), characterized by abnormal proton secretion. 7, 8 It is not known whether kAE1, like its RBCs' homolog band 3, plays a role as an anchoring structural protein.
However, kAE1 has been described to be part of a protein macro-complex involving ankyrin. 9 How SLC4A1 mutations affect HCO 3 transport in kidney is not completely understood. Based on heterologous expression studies in cell models or in Xenopus oocytes, some mutations have been proposed to provoke a mistargeting of the protein to the apical membrane, whereas others are thought to alter intrinsic transport properties of the protein, or to provoke an intracellular retention of the protein. 1, 2 However, it is difficult to draw firm conclusions from these studies because the protein was not expressed in its natural environment. Furthermore, some experiments testing the effects of a mutation have yielded different results when the protein was expressed in different cell models. Indeed, a recent study in a mouse knock-in model with the p.R607H mutation, corresponding to p.R589H in humans, reported different results. 10 Interestingly, because kAE1 is a truncated isoform of RBCs' AE1, all mutations affecting kAE1 also affect band 3. Taking advantage of this, we tested in RBC the effects of SLC4A1 mutations found in dRTA patients. We measured Cl -/HCO 3 transports and AE1/band 3 surface expression, as well as the RBC structural stability. Finally, we found that patients with dominant dRTA had both normal AE1 expression and function in RBCs, whereas those with recessive dRTA had both important morphological and functional anomalies. Red Blood Cell Indices, Reticulocyte Count, and Biochemistry Analyses All ethylenediamine tetraacetic acid blood samples were immediately shipped at þ4 C. A blood smear was provided to avoid artifacts (echinocytes, acanthocytes, spiculated dense red cells). Routine RBC indices were centrally obtained for each sample using a Sysmex auto-analyzer (XN 5000, Sysmex, Kobe, Japan). Blood smear were carefully screened by 2 independent cytologists who validated RBC morphology anomalies after MayÀGrünwald Giemsa coloration (MGG).
METHODS

Population
Ektacytometry
A 100-ml quantity of blood from each patient was run on an ektacytometer (LoRRca MaxSis, RR Mechatronics, Hoorn, Netherlands). 5, 11 Values for each patient were compared to those of an age-matched healthy control and to the reference values from the laboratory (R. Debré Hospital, Paris, France). Fresh blood was exposed to a shear stress and to an osmotic gradient. The laser beam diffraction pattern through the suspension was detected with a video camera. The RBC shapes changed from circular to elliptical as shear stress increased. Then, a deformability index or elongation index of cells was derived. The deformation of RBCs suspended in a viscous aqueous polyvinylpyrrolidone solution at defined values of applied shear stress of 30 Pa and at a constant temperature measurement of 37 C was monitored as a continuous function of suspending medium osmolality. The ektacytometry curve pattern and remarkable points were recorded: (i) Omin, reflecting the surface area-to-volume ratio, that is, the osmolality at the minimal deformability in hypo-osmolar area, or the osmolality when 50% of the , 200 mM sucrose, and 10 mM Hepes, pH 7.2, for Cltransport), generating an inwardly directed HCO 3 -/CO 2 gradient of 50 mEq/l and an outwardly directed Clgradient of equal magnitude. Data from 6 time courses were averaged and fit to a mono-exponential function using the simplex procedure of Biokine software (Bio-logic, Grenoble, France). This allowed the measurement of a transport constant (k). Then, permeability was calculated as the following equation:
where P is permeability (in mm Â s -1 ), k is transport constant (in s -1 ), and r is radius (in mm).
Protein Quantification
The AE1 surface expression on RBCs was detected using a FACSCanto II flow cytometer (BD BioSciences, Bedford, MA), after glutaraldehyde (0.025%) fixation and staining either with a monoclonal human anti- Eosin-5'-maleimide (EMA) dye test were also performed. 11, 13 For the Coomassie blue analysis, ghosts were prepared by hypotonic lysis, providing white ghosts. 14 Membrane proteins from whole ghost cell lysates were separated on sodium dodecyl sulphateÀpolyacrylamide gel electrophoresis (4%À12% acrylamide) in reducing conditions (2.8 mM b-mercaptoethanol) and stained with Coomassie blue. The densitometric analyses of data were performed using ImageJ 1.46j software (National Institutes of Health, Bethesda, MD).
Ghost Diameter Measurements
Ghosts preparation was the same as the one for stopped flow experiments except for pyranine concentration (1.5 mM). Of the ghosts, 2% were mounted between a slide and coverslip. Ghost diameters were measured using an Axio Observer Z1 microscope with an AxioCam MRm camera (Zeiss, Marly-le-Roi, France). An average of 800 fluorescent ghosts were measured for each genotype.
Statistical Analyses
Because of the low number of values in some groups, the distribution could not be supposed as normal. Therefore, we used only nonparametric tests: the MannÀWhitney test when 2 groups were compared, and the KruskalÀWallis test (with the Dunn multiple comparison test) when more than 2 groups were compared. Data are presented as their median and interquartile range (Q1ÀQ3). We considered a P value <0.05 as significant.
Data Availability
The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.
RESULTS
Included Patients
Fifteen patients were included. Table 1 shows their characteristics at diagnosis. Seven were diagnosed when they were adults. In children, the earliest diagnosis was performed within the first year of life. Two patients carried the characteristic molecular anomaly associated with South Asian ovalocytosis (SAO), which corresponds to the in-frame deletion of 27 nucleotides of SLC4A1 gene, leading to the loss of 9 amino acids ( Table 2 ). 15À27 Those 2 patients harbored other SLC4A1 mutations: one patient carried the recessive p.G701D mutation involved in dRTA, whereas the other carried the amino acid change p.E90K, involved in spherocytosis and the p.T581D one, involved in dRTA ( Figure 1 ). 26 27 we found 16 of them to be pathogenic or likely pathogenic (class 5 and 4, respectively), whereas 2 more were of uncertain significance (i.e., class 3).
Three patients had chronic kidney disease as defined by an estimated glomerular filtration rate of <60 ml/min per 1.73 m 2 , and 6 patients had overt metabolic acidosis as defined by [HCO 3 -] <20 mM. All patients had a history of nephrolithiasis and/or nephrocalcinosis. Six patients did not have a familial history of renal/metabolic injury. Dynamic testing of renal acidification was performed in 8 patients: 2 had an abnormal DU-B(PCO 2 ), 28 A total of 18 (12 different) gene mutations were identified in 15 patients. Two were predicted in silico, whereas 10 were previously reported. Thirteen patients had dominant distal renal tubular acidosis (dRTA). Three mutations were located at the C-terminal (C-term) domain, whereas 1 was found at the N-terminal (N-term) domain and 1 in the intracellular loop (ICL) between transmembrane domain (TM) 8 and TM9. Eight, 2, and 2 were found in TM6, TM7, and TM1, respectively. Following the American College of Medical Genetics (ACMG) recommendations published previously, 26 variants were classified into 5 categories (class 1, benign; class 2, likely benign; class 3, uncertain significance; class 4, likely pathogenic; and class 5, pathogenic) based on several criteria including population data, computational data, functional data, and segregation data. These criteria are weighted as very strong (PVS1), strong (PS1-4); moderate (PM1-6), or supporting (PP1-5). The mutations previously reported are presented with their references, as well as the references for the in vitro characterization of the mutation showing their pathogenicity. 30 (among those patients, 3 had also an abnormal response to the acute acid load test). Bone demineralization was reported in 4 patients.
Routine Hematological Analysis
No patient exhibited either overt anemia or other hemoglobinopathy (such as thalassemia or sickle cell disease). All had a normal mean corpuscular volume, and none had any anomalies in blood cells counts (Table 3) IN  IN   TM1  TM2  TM3  TM4  TM5  TM8  TM9   TM10  TM11  TM12  TM13  TM14   Patients 1 
Bicarbonate and Chloride Transports Through
Red Blood Cell Membranes Figure 3 shows the transport of HCO 3 and Clin ghosts. Diameters of ghosts ( Figure 3a ) obtained after RBC hypotonic lysis and resealing were not significantly different between groups (median 6.25, 5.88, and 7.67 mm in controls, dRTA SAOÀ, and dRTA SAOþ, respectively), and hence surfaces of exchange were not significantly different (123, 108, and 185 mm 2 in controls, dRTA SAOÀ, and dRTA SAOþ, respectively). Transport constants (k) for HCO 3 -( Figure 3b ) and Cl - (Figure 3c ) were significantly lower in dRTA SAOþ as compared to those in dRTA SAOÀ. Even though all dRTA SAOÀ patients had measurements close to those of the controls, the patient with the p.S525F mutation had k(HCO 3 -) values very close to those measured in dRTA SAOþ. Taken together, the relative values of k(HCO 3 -) and k(Cl -) allowed us to distinguish clearly dRTA SAOþ, whereas dRTA SAOÀ were merged within the controls (as plotted in Figure 3d ). For the patients in whom we measured surface of exchange, the calculated relative permeabilities (P) were lower in dRTA SAOþ than in the dRTA SAOÀ patients for both HCO 3 and Cl -, confirming the distinction between dRTA SAOþ to the others (Figure 3e ). Thus, dRTA SAOÀ express an AE1 protein that is capable of normal anion transports, whereas only dRTA SAOþ exhibit severe impairment in AE1-dependent anion exchange.
AE1 Expression in Red Blood Cells
To determine whether the lower transport activity of AE1 in dRTA SAOþ patients is related to lower membrane AE1 expression or to an intrinsic transport defect, we quantified its membrane expression ( Figure 4) . We used 3 different probes: EMA, Bric6, and Diego b (Figure 4b Figure 4a ) showed a reduced labeling in dRTA SAOþ patients (52%) compared with that in controls (100%) (P < 0.05) or dRTA SAOÀ (104%) as labeled with EMA, Bric6 (14%), or Diego b (54%). It is noteworthy that the patient with p.S525F mutation exhibited similar values to those of dRTA SAOÀ and controls. We also quantified the total amount of protein present in RBC membranes by quantifying the third band (i.e., band 3) by Coomassie blue staining after gel electrophoresis (Figure 4c) . No difference was observed between controls, dRTA SAOÀ, and dRTA SAOþ for the density of band 3 (P ¼ 0.26) even when band 3 density was normalized to the density of all polypeptides from same lane (P ¼ 0.37) (Figure 4d ).
Taken together, the aforementioned results indicate that expression of band 3 in dRTA SAOÀ is normal. In dRTA SAOþ, AE1 membrane expression is decreased, whereas the total amount of AE1 protein remains normal.
Finally, we show that only patients with SAO mutation exert severe RBC morphological anomalies with a large decrease in band 3 transport function that seems to be related to its membrane expression, whereas in dRTA patients without SAO mutation, both functional (transport) and morphological functions are preserved.
DISCUSSION
Taken together, our data show that mutations in SLC4A1 gene associated with dominant dRTA do not affect the function of the erythroid isoform band 3 unless the patient has an additional deletion causing SAO. The stopped-flow spectrophotometry analyses that we report in this context have some limitations. First, to measure the HCO 3 transport, we used an intracellular pH-sensitive probe (pyranine) as a proxy (not the direct HCO 3 concentration): we also report here results with the SPQ probe (measuring Clconcentration), the results of which are highly correlated with those of pyranine (r 2 ¼ 0.62, P < 0.0001). Previous reports have also shown similar results in heterologous models (Xenopus oocytes). 31, 32 or by using sulfate as a surrogate for chloride transport. 32 Second, the intracellular pH also depends on the carbonic anhydrase activity: to blunt this limiting step, we saturated the intracellular compartment with 2 mg/ml bovine carbonic anhydrase in every ghost. Finally, the systemic acidosis could impair the function of the AE1 protein: of note, patients with the most (acidotic) phenotype (at least at diagnosis) were not the ones carrying a SAO mutation. Nonetheless, this is the first report of in-depth assessment of RBC membrane disorders in patients with AE1-related dRTA. Very recently, an international cohort of dRTA patients was reported with many data on both the phenotypic diagnosis and evolution, 18 but the authors did not collect any hematological data. Previous studies that focused on the correlation between hematological and renal involvements of AE1 mutations were performed in patients carrying recessive mutations (mostly p.G701D) and the specific SAO deletion. [33] [34] [35] Moreover, when RBC anomalies were investigated, the authors reported only RBC shape and hemoglobin concentrations. Here, we report data on the transport activity of band 3 in RBCs and on the membrane/ cytoskeleton relationship, as well as of RBC shape and hemoglobin concentration. Other reports have also shown that SLC4A1 gene mutations are the main observed anomalies in dRTA, not only in Europe, 18 but also in south Asia. 36 Obvious hematological anomalies appear to be present only if patients carry the specific SAO anomaly, 23 which is consistent with our findings.
Knowing the precise (RBC) phenotype of patients bearing AE1 mutations could be of high interest at the time of the molecular diagnosis: as stated in the guidelines on the interpretation of molecular data, 27 to the discovery of new variants, for which interpretation could be very challenging. As an example, the patient carrying the p.S525F mutation had a class 3 variant (i.e., of uncertain significance). Interestingly, she had the lowest k(HCO 3 -) and P(HCO 3 -) values within the dRTA SAOÀ patients. Unfortunately, we did not have enough material to measure k(Cl -)/P(Cl -). Moreover, the transport of both Cland HCO 3 in patients carrying a mutation in position 589 appeared to be indistinguishable from those of controls. Most of the other mutations seem to have a behavior similar to that of p.R589H/C. Results from p.S525F remain questionable: RBC phenotype (transport) could lead to the interpretation of it as a differential genotype/phenotype correlation and could argue for a functional implication in the phenotype/disease (dRTA), bringing this variant to pathogenic, as it occurs in the domain important for the dimerization of the protein.
The recent crystallization structure of band 3 26 and structural analyses 4 help in understanding the differential mechanisms involved in several structural RBC diseases and the wide spectrum of interactions that AE1 develops with other proteins. In RBCs, the fulllength AE1 is expressed as oligomers (di-and tetramers) 1 : the dimers interact with cytosolic enzymes (such as aldolase, glyceraldehye-3-phosphate dehydrogenase, and carbonic anhydrase) at both the C-and N-terminal parts of the protein, whereas the tetramers interact with protein 4.2 and ankyrin, anchoring the complex (and thus the membrane) to the cytoskeleton. The interaction between AE1 and ankyrin (and thus the cytoskeleton) has also been shown in renal cells. 9 This is of particular importance, as some mutations in the SLC4A1 locus lead to a defect in this specific interaction with the cytoskeleton, and then lead to an impaired RBC shape called hereditary spherocytosis. 37 The fact that transport function of kAE1 leading to dRTA is impaired, whereas that of band 3 is preserved, argues for a rescue capacity in RBC. Besides the cytosolic interactions, RBC AE1 also interacts with membrane protein, such as glycophorin A (GPA). As with cytosolic proteins (such as ankyrin and stomatin 14 ), the interaction with GPA can modify or alter the conformation and the function of AE1. 38 More precisely, GPA could act as a protective chaperone by maintaining AE1 membrane expression. 39 That is consistent with the fact that in dRTA, kAE1 is less expressed at the membrane and is retained within the Golgi apparatus of kidney cells. 40 This could be related to other chaperones that avoid its expression (and function) at the a-ICs membrane. Further studies are needed to test whether modifying kAE1 expression by modulating chaperone function(s) could restore renal acidification ability.
Here, we also report differences in the quantitative assessment of band 3 expression in RBC from SAO patients: when assessed by labeling of extracellular domains of the protein, RBC membranes from SAO patients exhibited a decreased expression of AE1, whereas when assessed by total protein abundance, AE1 expression was not impaired, as previously reported. 31, 32 This could be related to such an important modification in the conformation of the protein that epitopes detected by immunolabeling could not be recognized, but the mobility shift previously reported 31 was not detected here.
In conclusion, AE1 dominant mutants associated with dRTA (i.e., known to alter transport in kidney) exert normal transport in RBCs. Transport in RBCs is altered only when the SAO mutant is additionally present.
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